Skip to main content
. 2020 Apr 9;20:295. doi: 10.1186/s12913-020-05115-7

Table 3.

Summary of the switch from vaccination schemes based on the pentavalent vaccine with whole-cell pertussis component (wP) plus various combinations/presentations of IPV or OPV vaccines assessed in scenarios 1 to 4 to the hexavalent vaccine with acellular pertussis component (aP) and IPV

graphic file with name 12913_2020_5115_Tab3_HTML.jpg

bOPV bivalent oral polio vaccine, IPV inactivated polio vaccine